T-SEM of 11 Major Psychiatric Disorders: Identification of Gene Expression Patterns for Cross-Disorder Risk and Drug Repurposing
Preprint
Abstract
Importance Psychiatric disorders display high levels of comorbidity and genetic overlap, necessitating multivariate approaches for parsing convergent and divergent psychiatric risk pathways. Identifying gene expression patterns underlying cross-disorder risk also stands to propel drug discovery and repurposing in the face of rising levels of polypharmacy. Objective To identify gene expression patterns underlying genetic convergence and divergence across psychiatric disorders along with existing pharmacological interventions that target these genes. Design This genomic study applied a multivariate transcriptomic method, Transcriptome-wide Structural Equation Modeling (T-SEM), to investigate gene expression patterns associated with four genomic factors indexing shared risk across 11 major psychiatric disorders. Follow-up tests, including overlap with gene sets for other outcomes and phenome-wide association studies, were conducted to better characterize T-SEM results. Public databases describing drug-gene pairs were used to identify drugs that could be repurposed to target genes found to be associated with cross-disorder risk. Main Outcomes and Measures Gene expression patterns associated with genomic factors or disorder-specific risk and existing drugs that target these genes. Results In total, T-SEM identified 451 genes whose expression was associated with the genomic factors and 41 genes with disorder-specific effects. We find the most hits for a Thought Disorders factor defined by bipolar disorder and schizophrenia. We identify 39 existing pharmacological interventions that could be repurposed to target gene expression hits for this same factor. Conclusions and Relevance The findings from this study shed light on patterns of gene expression associated with genetic overlap and uniqueness across psychiatric disorders. Future versions of the multivariate drug repurposing framework outlined here have the potential to identify novel pharmacological interventions for increasingly common, comorbid psychiatric presentations.Keywords
This publication has 64 references indexed in Scilit:
- Systematic identification of trans eQTLs as putative drivers of known disease associationsNature Genetics, 2013
- The role of the innate immune system in psychiatric disordersMolecular and Cellular Neuroscience, 2013
- Clinical Symptoms in Adults with Selective IgA Deficiency: A Case-Control StudyJournal of Clinical Immunology, 2013
- Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo‐controlled studyAlimentary Pharmacology & Therapeutics, 2012
- Exploiting drug-disease relationships for computational drug repositioningBriefings in Bioinformatics, 2011
- National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007Journal of the American Academy of Child & Adolescent Psychiatry, 2010
- National Trends in Psychotropic Medication Polypharmacy in Office-Based PsychiatryArchives of General Psychiatry, 2010
- The Neurocognitive Signature of Psychotic Bipolar DisorderBiological Psychiatry, 2007
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- CD40 AND CD154 IN CELL-MEDIATED IMMUNITYAnnual Review of Immunology, 1998